Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Mar. 15, 2023 | Jun. 30, 2022 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0000806517 | ||
Entity Registrant Name | PSYCHEMEDICS CORP | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2022 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2022 | ||
Document Transition Report | false | ||
Entity File Number | 1-13738 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 58-1701987 | ||
Entity Address, Address Line One | 289 Great Road | ||
Entity Address, City or Town | Acton | ||
Entity Address, State or Province | MA | ||
Entity Address, Postal Zip Code | 01720 | ||
City Area Code | 978 | ||
Local Phone Number | 206-8220 | ||
Title of 12(b) Security | Common stock. $0.005 par value | ||
Trading Symbol | PMD | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 26,900,000 | ||
Entity Common Stock, Shares Outstanding | 5,684,647 | ||
Auditor Firm ID | 243 | ||
Auditor Name | BDO USA, LLP | ||
Auditor Location | Boston, Massachusetts |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Current Assets: | ||
Cash | $ 4,750 | $ 1,992 |
Accounts receivable, net of allowance for doubtful accounts of $87 and $89 at December 31, 2022 and 2021, respectively | 3,739 | 4,116 |
Prepaid expenses and other current assets | 1,136 | 1,499 |
Income tax receivable | 339 | 2,678 |
Total Current Assets | 9,964 | 10,285 |
Property and equipment: | ||
Computer software | 4,648 | 4,521 |
Office furniture and equipment | 2,247 | 2,195 |
Laboratory equipment | 16,013 | 16,005 |
Leasehold improvements | 3,629 | 3,629 |
Property, Plant and Equipment, Gross, Ending Balance | 26,537 | 26,350 |
Accumulated depreciation and amortization | (21,964) | (19,659) |
Property, Plant and Equipment, Net, Total | 4,573 | 6,691 |
Other assets | 823 | 864 |
Deferred tax assets | 691 | 160 |
Operating lease right-of-use assets | 2,681 | 3,552 |
Total Assets | 18,732 | 21,552 |
Current Liabilities: | ||
Accounts payable | 448 | 994 |
Accrued expenses | 3,939 | 3,188 |
Current portion of long-term debt | 294 | 664 |
Current portion of operating lease liabilities | 1,037 | 984 |
Total Current Liabilities | 5,718 | 5,830 |
Long-term debt | 305 | 599 |
Long-term portion of operating lease liabilities | 1,938 | 2,880 |
Total Liabilities | 7,961 | 9,309 |
Commitments and Contingencies (Note 9) | ||
Shareholders' Equity: | ||
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding | 0 | 0 |
Common stock, $0.005 par value; 50,000 shares authorized 6,349 shares and 6,257 shares issued at December 31, 2022 and 2021, respectively, 5,681 shares outstanding and 5,589 shares outstanding at December 31, 2022 and 2021, respectively | 32 | 31 |
Additional paid-in capital | 34,275 | 33,478 |
Less - Treasury stock, at cost, 668 shares | (10,082) | (10,082) |
Accumulated deficit | (11,820) | (9,550) |
Accumulated other comprehensive loss | (1,634) | (1,634) |
Total Shareholders' Equity | 10,771 | 12,243 |
Total Liabilities and Shareholders' Equity | $ 18,732 | $ 21,552 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Allowance for doubtful accounts | $ 87 | $ 89 |
Preferred stock, par value (in dollars per share) | $ 0.005 | $ 0.005 |
Preferred stock, shares authorized (in shares) | 873 | 873 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.005 | $ 0.005 |
Common stock, shares authorized (in shares) | 50,000 | 50,000 |
Common stock, shares issued (in shares) | 6,349 | 6,257 |
Common stock, shares outstanding (in shares) | 5,681 | 5,589 |
Treasury stock, shares (in shares) | 668 | 668 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues | $ 25,240 | $ 24,909 | $ 21,360 |
Cost of revenues | 15,949 | 14,645 | 16,474 |
Gross profit | 9,291 | 10,264 | 4,886 |
Operating Expenses: | |||
General & administrative | 5,857 | 6,126 | 6,095 |
Marketing & selling | 3,191 | 2,799 | 3,577 |
Research & development | 1,326 | 1,130 | 1,280 |
Total Operating Expenses | 10,374 | 10,055 | 10,952 |
Operating (loss) income | (1,083) | 209 | (6,066) |
Other Income (Expense): | |||
Gain on forgiveness of PPP Loan | 0 | 2,181 | 0 |
Settlements | 0 | (3,150) | 0 |
Other income (expense) | 43 | (61) | (140) |
Total Other Income (Expense) | 43 | (1,030) | (140) |
Net loss before provision for (benefit from) income taxes | (1,040) | (821) | (6,206) |
Provision for (benefit from) income taxes | 44 | (156) | (2,347) |
Net loss | (1,084) | (665) | (3,859) |
Other Comprehensive Loss: | |||
Foreign currency translation, net of taxes | 0 | 0 | (10) |
Total Comprehensive Loss | $ (1,084) | $ (665) | $ (3,869) |
Basic net loss per share (in dollars per share) | $ (0.19) | $ (0.12) | $ (0.70) |
Diluted net loss per share (in dollars per share) | (0.19) | (0.12) | (0.70) |
Dividends declared, per share (in dollars per share) | $ 0.21 | $ 0.05 | $ 0.18 |
Weighted average common shares outstanding: | |||
Basic (in shares) | 5,626 | 5,549 | 5,524 |
Diluted (in shares) | 5,626 | 5,549 | 5,524 |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Treasury Stock [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2019 | 6,185 | 668 | ||||
Balance at Dec. 31, 2019 | $ 31,000 | $ 32,249,000 | $ (10,082,000) | $ (3,754,000) | $ (1,624,000) | $ 16,820,000 |
Shares issued – vested (in shares) | 20 | |||||
Tax withholding related to vested shares from employee stock plans | $ 0 | (9,000) | 0 | 0 | 0 | (9,000) |
Stock compensation expense | 563,000 | 563,000 | ||||
Cash dividends declared | 0 | 0 | 0 | (993,000) | 0 | (993,000) |
Net loss | 0 | 0 | 0 | (3,859,000) | 0 | (3,859,000) |
Foreign currency translation, net of taxes | $ 0 | 0 | $ 0 | 0 | (10,000) | (10,000) |
Balance (in shares) at Dec. 31, 2020 | 6,205 | 668 | ||||
Balance at Dec. 31, 2020 | $ 31,000 | 32,803,000 | $ (10,082,000) | (8,606,000) | (1,634,000) | 12,512,000 |
Shares issued – vested (in shares) | 51 | 0 | ||||
Tax withholding related to vested shares from employee stock plans | $ 0 | (72,000) | $ 0 | 0 | 0 | (72,000) |
Stock compensation expense | 0 | 743,000 | 0 | 0 | 0 | 743,000 |
Cash dividends declared | 0 | 0 | 0 | (279,000) | 0 | (279,000) |
Net loss | $ 0 | 0 | $ 0 | (665,000) | 0 | (665,000) |
Foreign currency translation, net of taxes | 0 | |||||
Exercise of stock options (in shares) | 1 | 0 | ||||
Exercise of stock options | $ 0 | 4,000 | $ 0 | 0 | 0 | 4,000 |
Balance (in shares) at Dec. 31, 2021 | 6,257 | 668 | ||||
Balance at Dec. 31, 2021 | $ 31,000 | 33,478,000 | $ (10,082,000) | (9,550,000) | (1,634,000) | 12,243,000 |
Shares issued – vested (in shares) | 91 | 0 | ||||
Tax withholding related to vested shares from employee stock plans | $ 0 | (78,000) | $ 0 | 0 | 0 | (78,000) |
Stock compensation expense | 0 | 872,000 | 0 | 0 | 0 | 872,000 |
Cash dividends declared | 0 | 0 | 0 | (1,186,000) | 0 | (1,186,000) |
Net loss | $ 0 | 0 | $ 0 | (1,084,000) | 0 | (1,084,000) |
Foreign currency translation, net of taxes | $ 0 | |||||
Exercise of stock options (in shares) | 1 | 0 | 1 | |||
Exercise of stock options | $ 0 | 4,000 | $ 0 | 0 | 0 | $ 4,000 |
Shares issued – vested | $ 1 | (1) | ||||
Balance (in shares) at Dec. 31, 2022 | 6,349 | 668 | ||||
Balance at Dec. 31, 2022 | $ 32,000 | $ 34,275,000 | $ (10,082,000) | $ (11,820,000) | $ (1,634,000) | $ 10,771,000 |
Consolidated Statements of Sh_2
Consolidated Statements of Shareholders' Equity (Parentheticals) - $ / shares | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Dividends declared, per share (in dollars per share) | $ 0.21 | $ 0.05 | $ 0.18 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities: | |||
Net loss | $ (1,084) | $ (665) | $ (3,859) |
Adjustments to reconcile net loss to net cash provided by operating activities: | |||
Forgiveness of PPP loan | 0 | (2,181) | 0 |
Depreciation and amortization | 2,367 | 2,784 | 2,691 |
ROU asset amortization | 949 | 906 | 935 |
Deferred income taxes | (531) | (371) | (339) |
Loss on sale of fixed assets | 0 | 0 | 94 |
Stock compensation expense | 872 | 743 | 563 |
Changes in operating assets and liabilities: | |||
Accounts receivable | 377 | (760) | 424 |
Prepaid expenses and other current assets | 363 | (585) | 392 |
Income tax receivable | 2,339 | (183) | (2,013) |
Accounts payable | (546) | 417 | (281) |
Operating lease liabilities | (967) | (1,078) | (914) |
Accrued expenses | 751 | 1,387 | (1,776) |
Net cash provided by (used in) operating activities | 4,890 | 414 | (4,083) |
Cash flows from investing activities: | |||
Proceeds from sale of fixed assets | 0 | 0 | 140 |
Other assets | (21) | (38) | (7) |
Purchases of property and equipment and capitalized software development costs | (187) | (182) | (991) |
Net cash used in investing activities | (208) | (220) | (858) |
Cash flows from financing activities: | |||
Cash dividends paid | (1,186) | (279) | (993) |
Proceeds from stock options and tax withholding related to vested shares from employee stock plans | (74) | (68) | (9) |
Payments of equipment financing | (664) | (688) | (678) |
Net cash (used in) provided by financing activities | (1,924) | (1,035) | 501 |
Effect of exchange rate changes on cash | 0 | 0 | (10) |
Net increase (decrease) in cash | 2,758 | (841) | (4,450) |
Cash, beginning of year | 1,992 | 2,833 | 7,283 |
Cash, end of year | 4,750 | 1,992 | 2,833 |
Supplemental disclosures of cash flow information: | |||
Cash paid for income taxes | 0 | 405 | 249 |
Cash paid for interest | 33 | 50 | 75 |
Cash paid for operating leases | 1,044 | 1,151 | 1,038 |
Right-of-use assets acquired through operating leases | 78 | 172 | 2,346 |
Non-cash investing and financing activities: | |||
Purchases of equipment through accounts payable and accrued liabilities | 0 | 241 | |
Paycheck Protection Program CARES Act [Member] | |||
Cash flows from financing activities: | |||
Proceeds from long term det | $ 0 | $ 0 | $ 2,181 |
Note 1 - Nature of Business
Note 1 - Nature of Business | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Company Overview Psychemedics Corporation (the “Company”) provides hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay and mass spectrometry to analyze hair to detect abused substances. The Company’s customers include Fortune 500 COVID- 19 The outbreak of coronavirus (“COVID- 19” 19 19’s The Coronavirus Aid, Relieve and Economic Security Act (“CARES”) Act, enacted on March 27, 2020, December 2020, 19. 19 December 31, 2021, December 31, 2020, 2020 Liquidity and Management s Plans At December 31, 2022, 12 may not no |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Risks and Uncertainties The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities at the date of purchase of 90 December 31, 2022, 2021, Property and Equipment Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software 3 5 Office furniture and equipment 3 7 Laboratory equipment 5 7 Leasehold improvements Lesser of estimated useful life or lease term The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in 2022, 2021 2020, not December 31, 2022, Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three five December 31, 2022, 2021, 2022, 2021 2020, may Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty December 31, 2022, December 31, 2021, 2022, 2021 2020, December 31, 2022, $62 five December 31, 2027 Allowance for Doubtful Accounts The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that may not not Revenue Recognition The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration ( none 30 60 The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 Year Ended December 31, 2022 2021 2020 Consolidated Revenue: Testing $ 21,608 $ 21,894 $ 19,068 Shipping / Collection (hair) 3,476 2,847 2,174 Other 156 168 118 Total Revenue $ 25,240 $ 24,909 $ 21,360 Testing Revenue Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred as they are typically not Research and Development Expenses The Company expenses all research and development costs as incurred. Contingencies Loss contingencies from legal proceedings and claims may Income Taxes The Company accounts for income taxes using the liability method pursuant to ASC 740, Income Taxes Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits may not not not no Significant Customers and Concentration of Credit Risk The Company had no customers that represented 10% December 31, 2022, 2021, 2020, one December 31, 2022 2021, Stock-Based Compensation The Company accounts for equity awards in accordance with ASC 718, Compensation Stock Compensation 718” 718 one not 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting no Stock compensation expense by statements of operations account is as follows (in thousands): Year Ended December 31, 2022 2021 2020 Cost of revenues $ 63 $ 63 $ 50 General & administrative 626 503 380 Marketing & selling 113 114 74 Research & development 70 63 59 Total stock compensation $ 872 $ 743 $ 563 See Note 7 Basic and Diluted Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows (in thousands): 2022 2021 2020 Weighted average common shares outstanding, basic 5,626 5,549 5,524 Dilutive common equivalent shares - - - Weighted average common shares outstanding, assuming dilution 5,626 5,549 5,524 For the years ended December 31, 2022, 2021 2020, not Fair Value Measurements The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms. Basis of Preparation and Consolidation The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. Segment Reporting The Company manages its operations as one 14 Recently Adopted Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 first 2023. 2016 13 not |
Note 3 - Accounts Receivable
Note 3 - Accounts Receivable | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | 3. The Company maintains an allowance for uncollectible accounts receivable based on management’s assessment of the collectability of its customer accounts by reviewing customer payment patterns and other relevant factors. The Company reviews the adequacy of the allowance for uncollectible accounts on a quarterly basis and adjusts the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. The following is a rollforward of the Company’s allowance for doubtful accounts (in thousands): As of December 31, 2022 2021 Balance, beginning of period $ 89 $ 37 Provision for doubtful accounts 9 55 Write-offs ( 11 ) ( 3 ) Balance, end of period $ 87 $ 89 |
Note 4 - Accrued Expenses
Note 4 - Accrued Expenses | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 4. Accrued expenses consist of the following (in thousands): As of December 31, 2022 2021 Accrued compensation and employee benefits $ 442 $ 507 Accrued vacation expense 409 373 Accrued taxes 771 200 Accrued shipping expense 338 488 Accrued legal settlement 1,150 1,150 Other accrued expenses 829 470 Total Accrued Expenses $ 3,939 $ 3,188 |
Note 5 - Income Taxes
Note 5 - Income Taxes | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 5. The income tax provision consists of the following (in thousands): Year Ended December 31, 2022 2021 2020 Current Federal $ 552 $ 131 $ ( 2,006 ) State 23 84 ( 2 ) Total Current 575 215 ( 2,008 ) Federal ( 959 ) ( 704 ) ( 13 ) State 428 333 ( 326 ) Total Deferred ( 531 ) ( 371 ) ( 339 ) Income Tax Provision $ 44 $ ( 156 ) $ ( 2,347 ) A reconciliation of the effective rate with the federal statutory rate is as follows: Year Ended December 31, 2022 2021 2020 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 12.0 % 10.4 % 4.4 % Permanent differences (0.4% ) 47.6 % 0.0 % Stock based compensation 0.5 % 1.4 % (0.4% ) Federal R&D Credits 8.9 % 0.0 % 1.6 % Foreign taxes, net of federal benefit 0.0 % (10.9% ) (2.2% ) Difference in tax rate for carryback claim 0.0 % 0.0 % 13.4 % Increase/(decrease) in valuation reserve (46.2% ) (50.5% ) 0.0 % Effective tax rate -4.2 % 19.0 % 37.8 % The change in effective tax rate from 2021 2022 2021 2021 2022. December 31, 2022, December 31, 2022, 2030 2040, not December 31, 2022, 2013 2022 2022, The components of the net deferred tax liabilities included in the accompanying balance sheets are as follows (in thousands): As of December 31, 2022 2021 Deferred Tax Assets Allowance for doubtful accounts $ 21 $ 21 Accrued expenses 414 129 Stock-based compensation 381 325 R&D tax credits 1,086 1,083 Operating lease 701 944 Capitalized research expenses 404 - NOL carryforward 72 219 Gross Deferred Tax Assets 3,079 2,721 Valuation Allowance ( 895 ) ( 414 ) Deferred Tax Assets After Valuation Allowance 2,184 2,307 Deferred Tax Liabilities Excess of tax over book depreciation and amortization ( 783 ) ( 1,249 ) Prepaid expenses ( 78 ) ( 61 ) Operating lease ( 632 ) ( 837 ) Gross Deferred Tax Liabilities ( 1,493 ) ( 2,147 ) Net Deferred Tax Assets $ 691 $ 160 Income taxes are recorded in accordance with FASB ASC Topic 740, 740” not not 2019 12 January 1, 2021, no ASC 740 two first not second 50% may may not December 31, 2022, 2021, The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may may December 31, 2022, 2021 2020 not |
Note 6 - Preferred Stock
Note 6 - Preferred Stock | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 6. The Board of Directors has the authority to designate authorized preferred shares in one no |
Note 7 - Stock-based Awards
Note 7 - Stock-based Awards | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 7. The 2006 2006 ten May 2021, 2006 December 31, 2022, 2006 The fair value of the SUAs is determined by the closing price on the date of grant. The fair value of options is determined using a Black-Scholes model. The SUAs and options vest over a period of two four 2016 09 2016, no On April 4, 2022, two thousand May 20, 2022, August 12, 2022, The following table represents all shares granted by the Company under the 2006 three Grant Date Type Shares Fair Value August 12, 2022 SUA 18 $ 6.65 May 20, 2022 SUA 126 $ 6.51 April 4, 2022 SUA 2 $ 7.04 May 13, 2021 SUA 116 $ 6.55 March 16, 2021 SUA 2 $ 7.04 January 25, 2021 SUA 2 $ 5.54 December 16, 2020 SUA 5 $ 4.71 November 11, 2020 Options 40 $ 1.13 November 11, 2020 SUA 190 $ 4.07 ( 1 The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 November 11, 2020, No December 31, 2022, 2021. December 31, 2020, December 31, 2022, 2021 2020, A summary of the Company’s stock option activity is as follows (in thousands, except price per share): Number of Weighted Average Weighted Aggregate (2) Outstanding, December 31, 2021 574 $ 14.23 6.1 years $ 100 Granted - $ - Exercised (1 ) $ 4.07 Forfeited (1 ) $ 4.07 Canceled (64 ) $ 15.03 Outstanding, December 31, 2022 508 $ 14.19 5.1 years $ 25 Exercisable, December 31, 2022 467 $ 14.70 4.9 years $ 14 ( 2 The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 December 31, 2022, 2021 A summary of the Company’s stock unit award activity is as follows (in thousands, except price per share): Number of Shares Weighted Average Grant-Date Fair Value per Share (3) Outstanding & Unvested, December 31, 2021 224 $ 5.48 Granted 146 $ 6.53 Converted to common stock ( 90 ) $ 6.33 Cancelled ( 12 ) $ 6.29 Forfeited ( 30 ) $ 6.26 Outstanding & Unvested, December 31, 2022 238 $ 6.10 ( 3 Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares. The fair value of stock unit award vesting was $548 thousand, $296 thousand and $274 thousand for the years ended December 31, 2022, 2021, 2020, December 31, 2022, 2021, 2020, As of December 31, 2022, 2006 December 31, 2022, The Board of Directors approved the accelerated vesting of 35 thousand SUAs to certain directors upon retirement from the Board of the Company during the year ended December 31, 2022. December 31, 2022. |
Note 8 - Employee Benefit Plan
Note 8 - Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | 8. The Psychemedics Corporation 401 “401 401 21 401 may, not zero zero December 31, 2022, 2021 2020, |
Note 9 - Commitments and Contin
Note 9 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 9. Commitments The Company leases certain of its facilities and equipment under operating lease agreements expiring on various dates through December 2026. 2022, 2021 2020, 10 Contingencies In the normal course of business, we are subject to contingencies, such as legal proceedings and claims arising out of our business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product liability, contractual claims and tax matters. We recognize accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. These estimates are subject to uncertainties that are difficult to predict and, as such, actual results could vary from these estimates. Settlements On December 6, 2021, No. 2:20 06624 In the binding MOU, the parties agreed to settle this matter for a payment by the Company of $1.2 million in exchange for the dismissal of the California Lawsuit and a customary release of liability, subject only to final court approval and the process described below. Factoring in that process, the Company estimates that the settlement funds will be dispersed in the second 2023, Although the Company believes that the allegations in the California Lawsuit lack merit, it agreed at a mediation to enter into the binding MOU to settle the claims in the California Lawsuit in order to avoid potentially significant legal fees, other expenses, and management time that would have to be devoted to protracted litigation in California regarding its wage and hour laws. The foregoing was also impacted in part by new California case law in February 2021 June 9, 2017. The MOU assumes class certification for purposes of the settlement only. The settlement amount of $1.2 not 2004. December 31, 2022, 2021 |
Note 10 - Operating Leases
Note 10 - Operating Leases | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 10. Operating Leases The Company has five no not not The weighted average discount rate used for leases as of December 31, 2022, December 31, 2022, twelve December 31, 2022, 2021, Maturities and balance sheet presentation of the Company’s lease liabilities for all operating leases as of December 31, 2022, 2023 $ 1,134 2024 1,061 2025 553 2026 460 Total lease payments 3,208 Less: interest ( 233 ) Present value of lease liabilities $ 2,975 Current operating lease liabilities $ 1,037 Long-term operating lease liabilities 1,938 Total $ 2,975 |
Note 11 - Debt and Other Financ
Note 11 - Debt and Other Financing Arrangements | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 11. Debt and Other Financing Arrangements On March 20, 2014, March 23, 2021, 30 60 first 2020 2021. December 31, 2022. Under the Equipment Loan Arrangement, the Company executed notes on various dates between March 24, 2014, December 4, 2019 2022 2021, December 31, 2022, December 31, 2022, December 31, 2022, On May 1, 2020, May 4, 2022. one 1% In July 2021, 100% 2021 The annual principal repayment requirements for debt obligations as of December 31, 2022, 2023 $ 294 2024 305 Long-term debt from equipment financing 599 Less current portion of long-term debt from equipment financing (294 ) Long-term debt from equipment financing, net of current portion $ 305 |
Note 12 - Other Income (Expense
Note 12 - Other Income (Expense) | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Other Income and Other Expense Disclosure [Text Block] | 12. Interest expense for the year ended December 31, 2022, 2021, 2020 December 31, 2022, 2021, 2020. |
Note 13 - Business Segment Repo
Note 13 - Business Segment Reporting | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 13. The Company manages its operations as one Year Ended December 31, 2022 2021 2020 Consolidated Revenue: United States $ 24,509 $ 23,584 $ 19,486 International 731 1,325 1,874 Total Revenue $ 25,240 $ 24,909 $ 21,360 |
Note 14 - Subsequent Event
Note 14 - Subsequent Event | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 14. On March 21, 2023, April 10, 2023 March 31, 2023. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Risks and Uncertainties [Policy Text Block] | Risks and Uncertainties The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not |
Use of Estimates, Policy [Policy Text Block] | Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities at the date of purchase of 90 December 31, 2022, 2021, |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software 3 5 Office furniture and equipment 3 7 Laboratory equipment 5 7 Leasehold improvements Lesser of estimated useful life or lease term The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in 2022, 2021 2020, not December 31, 2022, |
Research, Development, and Computer Software, Policy [Policy Text Block] | Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three five December 31, 2022, 2021, 2022, 2021 2020, may |
Other Assets [Policy Text Block] | Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty December 31, 2022, December 31, 2021, 2022, 2021 2020, December 31, 2022, $62 five December 31, 2027 |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Allowance for Doubtful Accounts The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that may not not |
Revenue [Policy Text Block] | Revenue Recognition The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration ( none 30 60 The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 Year Ended December 31, 2022 2021 2020 Consolidated Revenue: Testing $ 21,608 $ 21,894 $ 19,068 Shipping / Collection (hair) 3,476 2,847 2,174 Other 156 168 118 Total Revenue $ 25,240 $ 24,909 $ 21,360 Testing Revenue Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred as they are typically not |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Expenses The Company expenses all research and development costs as incurred. |
Contingent Liability Reserve Estimate, Policy [Policy Text Block] | Contingencies Loss contingencies from legal proceedings and claims may |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes using the liability method pursuant to ASC 740, Income Taxes |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits may not not not no |
Major Customers, Policy [Policy Text Block] | Significant Customers and Concentration of Credit Risk The Company had no customers that represented 10% December 31, 2022, 2021, 2020, one December 31, 2022 2021, |
Share-Based Payment Arrangement [Policy Text Block] | Stock-Based Compensation The Company accounts for equity awards in accordance with ASC 718, Compensation Stock Compensation 718” 718 one not 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting no Stock compensation expense by statements of operations account is as follows (in thousands): Year Ended December 31, 2022 2021 2020 Cost of revenues $ 63 $ 63 $ 50 General & administrative 626 503 380 Marketing & selling 113 114 74 Research & development 70 63 59 Total stock compensation $ 872 $ 743 $ 563 See Note 7 |
Earnings Per Share, Policy [Policy Text Block] | Basic and Diluted Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows (in thousands): 2022 2021 2020 Weighted average common shares outstanding, basic 5,626 5,549 5,524 Dilutive common equivalent shares - - - Weighted average common shares outstanding, assuming dilution 5,626 5,549 5,524 For the years ended December 31, 2022, 2021 2020, not |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value Measurements The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms. |
Basis of Presentation and Consolidation, Policy [Policy Text Block] | Basis of Preparation and Consolidation The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. |
Segment Reporting, Policy [Policy Text Block] | Segment Reporting The Company manages its operations as one 14 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 first 2023. 2016 13 not |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | Computer software 3 5 Office furniture and equipment 3 7 Laboratory equipment 5 7 Leasehold improvements Lesser of estimated useful life or lease term |
Disaggregation of Revenue [Table Text Block] | Year Ended December 31, 2022 2021 2020 Consolidated Revenue: Testing $ 21,608 $ 21,894 $ 19,068 Shipping / Collection (hair) 3,476 2,847 2,174 Other 156 168 118 Total Revenue $ 25,240 $ 24,909 $ 21,360 |
Schedule of Stock Based Compensation Expense [Table Text Block] | Year Ended December 31, 2022 2021 2020 Cost of revenues $ 63 $ 63 $ 50 General & administrative 626 503 380 Marketing & selling 113 114 74 Research & development 70 63 59 Total stock compensation $ 872 $ 743 $ 563 |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | 2022 2021 2020 Weighted average common shares outstanding, basic 5,626 5,549 5,524 Dilutive common equivalent shares - - - Weighted average common shares outstanding, assuming dilution 5,626 5,549 5,524 |
Note 3 - Accounts Receivable (T
Note 3 - Accounts Receivable (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block] | As of December 31, 2022 2021 Balance, beginning of period $ 89 $ 37 Provision for doubtful accounts 9 55 Write-offs ( 11 ) ( 3 ) Balance, end of period $ 87 $ 89 |
Note 4 - Accrued Expenses (Tabl
Note 4 - Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | As of December 31, 2022 2021 Accrued compensation and employee benefits $ 442 $ 507 Accrued vacation expense 409 373 Accrued taxes 771 200 Accrued shipping expense 338 488 Accrued legal settlement 1,150 1,150 Other accrued expenses 829 470 Total Accrued Expenses $ 3,939 $ 3,188 |
Note 5 - Income Taxes (Tables)
Note 5 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Year Ended December 31, 2022 2021 2020 Current Federal $ 552 $ 131 $ ( 2,006 ) State 23 84 ( 2 ) Total Current 575 215 ( 2,008 ) Federal ( 959 ) ( 704 ) ( 13 ) State 428 333 ( 326 ) Total Deferred ( 531 ) ( 371 ) ( 339 ) Income Tax Provision $ 44 $ ( 156 ) $ ( 2,347 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year Ended December 31, 2022 2021 2020 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 12.0 % 10.4 % 4.4 % Permanent differences (0.4% ) 47.6 % 0.0 % Stock based compensation 0.5 % 1.4 % (0.4% ) Federal R&D Credits 8.9 % 0.0 % 1.6 % Foreign taxes, net of federal benefit 0.0 % (10.9% ) (2.2% ) Difference in tax rate for carryback claim 0.0 % 0.0 % 13.4 % Increase/(decrease) in valuation reserve (46.2% ) (50.5% ) 0.0 % Effective tax rate -4.2 % 19.0 % 37.8 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | As of December 31, 2022 2021 Deferred Tax Assets Allowance for doubtful accounts $ 21 $ 21 Accrued expenses 414 129 Stock-based compensation 381 325 R&D tax credits 1,086 1,083 Operating lease 701 944 Capitalized research expenses 404 - NOL carryforward 72 219 Gross Deferred Tax Assets 3,079 2,721 Valuation Allowance ( 895 ) ( 414 ) Deferred Tax Assets After Valuation Allowance 2,184 2,307 Deferred Tax Liabilities Excess of tax over book depreciation and amortization ( 783 ) ( 1,249 ) Prepaid expenses ( 78 ) ( 61 ) Operating lease ( 632 ) ( 837 ) Gross Deferred Tax Liabilities ( 1,493 ) ( 2,147 ) Net Deferred Tax Assets $ 691 $ 160 |
Note 7 - Stock-based Awards (Ta
Note 7 - Stock-based Awards (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] | Grant Date Type Shares Fair Value August 12, 2022 SUA 18 $ 6.65 May 20, 2022 SUA 126 $ 6.51 April 4, 2022 SUA 2 $ 7.04 May 13, 2021 SUA 116 $ 6.55 March 16, 2021 SUA 2 $ 7.04 January 25, 2021 SUA 2 $ 5.54 December 16, 2020 SUA 5 $ 4.71 November 11, 2020 Options 40 $ 1.13 November 11, 2020 SUA 190 $ 4.07 |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Number of Weighted Average Weighted Aggregate (2) Outstanding, December 31, 2021 574 $ 14.23 6.1 years $ 100 Granted - $ - Exercised (1 ) $ 4.07 Forfeited (1 ) $ 4.07 Canceled (64 ) $ 15.03 Outstanding, December 31, 2022 508 $ 14.19 5.1 years $ 25 Exercisable, December 31, 2022 467 $ 14.70 4.9 years $ 14 |
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] | Number of Shares Weighted Average Grant-Date Fair Value per Share (3) Outstanding & Unvested, December 31, 2021 224 $ 5.48 Granted 146 $ 6.53 Converted to common stock ( 90 ) $ 6.33 Cancelled ( 12 ) $ 6.29 Forfeited ( 30 ) $ 6.26 Outstanding & Unvested, December 31, 2022 238 $ 6.10 |
Note 10 - Operating Leases (Tab
Note 10 - Operating Leases (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | 2023 $ 1,134 2024 1,061 2025 553 2026 460 Total lease payments 3,208 Less: interest ( 233 ) Present value of lease liabilities $ 2,975 Current operating lease liabilities $ 1,037 Long-term operating lease liabilities 1,938 Total $ 2,975 |
Note 11 - Debt and Other Fina_2
Note 11 - Debt and Other Financing Arrangements (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Schedule of Long-Term Debt Instruments [Table Text Block] | 2023 $ 294 2024 305 Long-term debt from equipment financing 599 Less current portion of long-term debt from equipment financing (294 ) Long-term debt from equipment financing, net of current portion $ 305 |
Note 13 - Business Segment Re_2
Note 13 - Business Segment Reporting (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Revenue from External Customers by Geographic Areas [Table Text Block] | Year Ended December 31, 2022 2021 2020 Consolidated Revenue: United States $ 24,509 $ 23,584 $ 19,486 International 731 1,325 1,874 Total Revenue $ 25,240 $ 24,909 $ 21,360 |
Note 1 - Nature of Business (De
Note 1 - Nature of Business (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2022 | |
Income Tax Benefit CARES Act | $ 2,600 | $ 200 | |
Cash and Cash Equivalents, at Carrying Value, Total | $ 1,992 | $ 4,750 |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 USD ($) shares | Dec. 31, 2021 USD ($) shares | Dec. 31, 2020 USD ($) shares | |
Cash Equivalents, at Carrying Value, Total | $ 0 | $ 0 | |
Depreciation, Depletion and Amortization, Nonproduction, Total | 2,400 | 2,800 | $ 2,700 |
Property, Plant and Equipment, Net, Ending Balance | 4,573 | $ 6,691 | |
Finite-Lived Intangible Asset, Expected Amortization, Year One | 62 | ||
Finite-Lived Intangible Asset, Expected Amortization, Year Two | 62 | ||
Finite-Lived Intangible Asset, Expected Amortization, Year Three | 62 | ||
Finite-Lived Intangible Asset, Expected Amortization, Year Four | 62 | ||
Finite-Lived Intangible Asset, Expected Amortization, Year Five | 62 | ||
Finite-Lived Intangible Asset, Expected Amortization, after Year Five | $ 109 | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 508 | 574 | 588 |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | |||
Number of Major Customers | 0 | 0 | 0 |
Customer Concentration Risk [Member] | Accounts Receivable [Member] | |||
Number of Major Customers | 1 | 1 | 1 |
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member] | |||
Concentration Risk, Percentage | 11% | 12% | |
Patents [Member] | |||
Amortization, Total | $ 62 | $ 62 | $ 62 |
Finite-Lived Intangible Asset, Useful Life (Year) | 20 years | ||
Legal Cost Capitalized | $ 1,100 | 1,100 | |
Legal Cost Capitalized, Amortization | 500 | 400 | |
Legal Cost Capitalized, Net | 600 | 700 | |
Capitalized Software and Equipment [Member] | |||
Property, Plant and Equipment, Net, Ending Balance | 500 | ||
Software Development [Member] | |||
Software Development Cost Capitalized | 127 | 99 | |
Amortization, Total | $ 282 | $ 421 | $ 293 |
Software Development [Member] | Minimum [Member] | |||
Property, Plant and Equipment, Useful Life (Year) | 3 years | ||
Software Development [Member] | Maximum [Member] | |||
Property, Plant and Equipment, Useful Life (Year) | 5 years |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details) | 12 Months Ended |
Dec. 31, 2022 | |
Minimum [Member] | Office Equipment [Member] | |
Property, plant and equipment, useful life (Year) | 3 years |
Minimum [Member] | Laboratory Equipment [Member] | |
Property, plant and equipment, useful life (Year) | 5 years |
Minimum [Member] | Computer Software, Intangible Asset [Member] | |
Property, plant and equipment, useful life (Year) | 3 years |
Maximum [Member] | Office Equipment [Member] | |
Property, plant and equipment, useful life (Year) | 7 years |
Maximum [Member] | Laboratory Equipment [Member] | |
Property, plant and equipment, useful life (Year) | 7 years |
Maximum [Member] | Computer Software, Intangible Asset [Member] | |
Property, plant and equipment, useful life (Year) | 5 years |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues | $ 25,240 | $ 24,909 | $ 21,360 |
Testing [Member] | |||
Revenues | 21,608 | 21,894 | 19,068 |
Shipping/Collection (Hair) [Member] | |||
Revenues | 3,476 | 2,847 | 2,174 |
Other Revenue [Member] | |||
Revenues | $ 156 | $ 168 | $ 118 |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Stock compensation expense | $ 872 | $ 743 | $ 563 |
Cost of Sales [Member] | |||
Stock compensation expense | 63 | 63 | 50 |
General and Administrative Expense [Member] | |||
Stock compensation expense | 626 | 503 | 380 |
Selling and Marketing Expense [Member] | |||
Stock compensation expense | 113 | 114 | 74 |
Research and Development Expense [Member] | |||
Stock compensation expense | $ 70 | $ 63 | $ 59 |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Weighted average common shares outstanding, basic (in shares) | 5,626 | 5,549 | 5,524 |
Dilutive common equivalent shares (in shares) | 0 | 0 | 0 |
Weighted average common shares outstanding, assuming dilution (in shares) | 5,626 | 5,549 | 5,524 |
Note 3 - Accounts Receivable -
Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Balance, beginning of period | $ 89 | $ 37 |
Provision for doubtful accounts | 9 | 55 |
Write-offs | (11) | (3) |
Balance, end of period | $ 87 | $ 89 |
Note 4 - Accrued Expenses - Sum
Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Accrued compensation and employee benefits | $ 442 | $ 507 |
Accrued vacation expense | 409 | 373 |
Accrued taxes | 771 | 200 |
Accrued shipping expense | 338 | 488 |
Accrued legal settlement | 1,150 | 1,150 |
Other accrued expenses | 829 | 470 |
Total Accrued Expenses | $ 3,939 | $ 3,188 |
Note 5 - Income Taxes (Details
Note 5 - Income Taxes (Details Textual) $ in Thousands | 12 Months Ended |
Dec. 31, 2022 USD ($) | |
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | |
Operating Loss Carryforwards | $ 0 |
Tax Credit Carryforward, Amount | 0 |
State and Local Jurisdiction [Member] | |
Operating Loss Carryforwards | 1,300 |
Operating Loss Carryforwards, Subject to Expiration | 1,200 |
Operating Loss Carryforwards, Not Subject to Expiration | 100 |
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | |
Tax Credit Carryforward, Amount | $ 1,400 |
Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total | 12% |
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | 8.30% |
Note 5 - Income Taxes - Summary
Note 5 - Income Taxes - Summary of Income Tax Provision (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Federal | $ 552 | $ 131 | $ (2,006) |
State | 23 | 84 | (2) |
Total Current | 575 | 215 | (2,008) |
Federal | (959) | (704) | (13) |
State | 428 | 333 | (326) |
Total Deferred | (531) | (371) | (339) |
Income Tax Provision | $ 44 | $ (156) | $ (2,347) |
Note 5 - Income Taxes - Reconci
Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Federal statutory rate | 21% | 21% | 21% |
State income taxes, net of federal benefit | 12% | 10.40% | 4.40% |
Permanent differences | (0.40%) | 47.60% | 0% |
Stock based compensation | 0.50% | 1.40% | (0.40%) |
Federal R&D Credits | 8.90% | 0% | 1.60% |
Foreign taxes, net of federal benefit | 0% | (10.90%) | (2.20%) |
Difference in tax rate for carryback claim | 0% | 0% | 13.40% |
Increase/(decrease) in valuation reserve | (46.20%) | (50.50%) | 0% |
Effective tax rate | (4.20%) | 19% | 37.80% |
Note 5 - Income Taxes - Compone
Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Deferred Tax Assets | ||
Allowance for doubtful accounts | $ 21 | $ 21 |
Accrued expenses | 414 | 129 |
Stock-based compensation | 381 | 325 |
R&D tax credits | 1,086 | 1,083 |
Operating lease | 701 | 944 |
Capitalized research expenses | 404 | 0 |
NOL carryforward | 72 | 219 |
Gross Deferred Tax Assets | 3,079 | 2,721 |
Valuation Allowance | (895) | (414) |
Deferred Tax Assets After Valuation Allowance | 2,184 | 2,307 |
Deferred Tax Liabilities | ||
Excess of tax over book depreciation and amortization | (783) | (1,249) |
Prepaid expenses | (78) | (61) |
Operating lease | (632) | (837) |
Gross Deferred Tax Liabilities | (1,493) | (2,147) |
Net Deferred Tax Assets | $ 691 | $ 160 |
Note 7 - Stock-based Awards (De
Note 7 - Stock-based Awards (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |||||||||
Aug. 12, 2022 | May 20, 2022 | Apr. 04, 2022 | Nov. 11, 2020 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2006 | May 31, 2021 | Jan. 31, 2019 | |
Share Price (in dollars per share) | $ 1.13 | $ 4.90 | $ 7.02 | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 3.47 | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $ 548 | $ 296 | $ 274 | |||||||
Conversion of Stock, Amount Issued | 650 | $ 501 | $ 115 | |||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 1,200 | |||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 3 months 18 days | |||||||||
Stock Unit Award [Member] | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 18 | 126 | 2,000 | 146 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 6.53 | $ 6.55 | $ 4.89 | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares) | 35 | |||||||||
Share-Based Payment Arrangement, Accelerated Cost | $ 230 | |||||||||
Share-Based Payment Arrangement, Option [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 4.07 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 45% | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 0.90% | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 4% | |||||||||
Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 2 years | |||||||||
Minimum [Member] | Share-Based Payment Arrangement, Option [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year) | 5 years 9 months | |||||||||
Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | |||||||||
Maximum [Member] | Share-Based Payment Arrangement, Option [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year) | 6 years 3 months | |||||||||
Incentive Plan 2006 [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 183 | 1,600 | 1,200 | |||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 1,032 |
Note 7 - Stock-based Awards - S
Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) shares in Thousands | 12 Months Ended | |
Dec. 31, 2022 $ / shares shares | ||
November 11, 2020 [Member] | ||
Shares granted (in shares) | shares | 40 | |
Fair value per share (in dollars per share) | $ / shares | $ 1.13 | |
Shares granted (in shares) | shares | 40 | |
Fair value per share (in dollars per share) | $ / shares | $ 1.13 | |
Stock Unit Award [Member] | August 12, 2022 [Member] | ||
Shares granted (in shares) | shares | 18 | |
Fair value per share (in dollars per share) | $ / shares | $ 6.65 | [1] |
Shares granted (in shares) | shares | 18 | |
Fair value per share (in dollars per share) | $ / shares | $ 6.65 | [1] |
Stock Unit Award [Member] | May 20, 2022 [Member] | ||
Shares granted (in shares) | shares | 126 | |
Fair value per share (in dollars per share) | $ / shares | $ 6.51 | [1] |
Shares granted (in shares) | shares | 126 | |
Fair value per share (in dollars per share) | $ / shares | $ 6.51 | [1] |
Stock Unit Award [Member] | April 4, 2022 [Member] | ||
Shares granted (in shares) | shares | 2 | |
Fair value per share (in dollars per share) | $ / shares | $ 7.04 | [1] |
Shares granted (in shares) | shares | 2 | |
Fair value per share (in dollars per share) | $ / shares | $ 7.04 | [1] |
Stock Unit Award [Member] | May 13, 2021 [Member] | ||
Shares granted (in shares) | shares | 116 | |
Fair value per share (in dollars per share) | $ / shares | $ 6.55 | [1] |
Shares granted (in shares) | shares | 116 | |
Fair value per share (in dollars per share) | $ / shares | $ 6.55 | [1] |
Stock Unit Award [Member] | March 16, 2021 [Member] | ||
Shares granted (in shares) | shares | 2 | |
Fair value per share (in dollars per share) | $ / shares | $ 7.04 | [1] |
Shares granted (in shares) | shares | 2 | |
Fair value per share (in dollars per share) | $ / shares | $ 7.04 | [1] |
Stock Unit Award [Member] | January 25, 2021 [Member] | ||
Shares granted (in shares) | shares | 2 | |
Fair value per share (in dollars per share) | $ / shares | $ 5.54 | [1] |
Shares granted (in shares) | shares | 2 | |
Fair value per share (in dollars per share) | $ / shares | $ 5.54 | [1] |
Stock Unit Award [Member] | December 16, 2020 [Member] | ||
Shares granted (in shares) | shares | 5 | |
Fair value per share (in dollars per share) | $ / shares | $ 4.71 | [1] |
Shares granted (in shares) | shares | 5 | |
Fair value per share (in dollars per share) | $ / shares | $ 4.71 | [1] |
Stock Unit Award [Member] | November 11, 2020 [Member] | ||
Shares granted (in shares) | shares | 190 | |
Fair value per share (in dollars per share) | $ / shares | $ 4.07 | |
Shares granted (in shares) | shares | 190 | |
Fair value per share (in dollars per share) | $ / shares | $ 4.07 | |
[1]The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years. The options granted on May 3, 2019, have a fair value of $2.99 per share based on the $10.60 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 41% volatility, 2.4% interest rate and a 3.9% dividend yield rate. The options granted on November 11, 2020, have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0%dividend yield rate. No options were granted during fiscal year ended December 31, 2021. For options granted during fiscal years ended December 31, 2020, and 2019, the weighted average grant date fair values were $3.47, and $3.40,respectively. For SUAs granted during fiscal years ended December 31, 2021, 2020 and 2019, the weighted average grant date fair values were $6.55, $4.89, and $12.01, respectively. |
Note 7 - Stock-based Awards -_2
Note 7 - Stock-based Awards - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | ||
Outstanding (in shares) | 574 | ||
Outstanding, weighted average exercise price (in dollars per share) | $ 14.23 | ||
Outstanding, weighted average remaining contractual life (Year) | 5 years 1 month 6 days | 6 years 1 month 6 days | |
Outstanding, aggregate intrinsic value | $ 25 | [1] | $ 100 |
Exercised (in shares) | (1) | ||
Exercised, weighted average exercise price (in dollars per share) | $ 4.07 | ||
Forfeited (in shares) | (1) | ||
Forfeited, weighted average exercise price (in dollars per share) | $ 4.07 | ||
Canceled (in shares) | (64) | ||
Canceled (in dollars per share) | $ 15.03 | ||
Outstanding (in shares) | 508 | 574 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 14.19 | $ 14.23 | |
Exercisable (in shares) | 467 | ||
Exercisable, weighted average exercise price (in dollars per share) | $ 14.70 | ||
Exercisable, weighted average remaining contractual life (Year) | 4 years 10 months 24 days | ||
Exercisable, aggregate intrinsic value | $ 14 | ||
[1]The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2021, and 2020 was $7.02 and $5.09, respectively. |
Note 7 - Stock-based Awards - N
Note 7 - Stock-based Awards - Nonvested Award Activity (Details) - Stock Unit Award [Member] - $ / shares shares in Thousands | 12 Months Ended | ||||
Aug. 12, 2022 | May 20, 2022 | Apr. 04, 2022 | Dec. 31, 2022 | ||
Outstanding & Unvested at beginning of period (in shares) | 224 | ||||
Outstanding & Unvested at beginning of period, weighted average price per share (in dollars per share) | [1] | $ 5.48 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 18 | 126 | 2,000 | 146 | |
Granted, weighted average price per share (in dollars per share) | [1] | $ 6.53 | |||
Converted to common stock (in shares) | (90) | ||||
Converted to common stock, weighted average price per share (in dollars per share) | [1] | $ 6.33 | |||
Cancelled (in shares) | (12) | ||||
Cancelled, weighted average price per share (in dollars per share) | [1] | $ 6.29 | |||
Forfeited (in shares) | (30) | ||||
Forfeited, weighted average price per share (in dollars per share) | [1] | $ 6.26 | |||
Outstanding & Unvested at end of period (in shares) | 238 | ||||
Outstanding & Unvested at end of period, weighted average price per share (in dollars per share) | [1] | $ 6.10 | |||
[1]Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares. |
Note 8 - Employee Benefit Plan
Note 8 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 0 | $ 0 | $ 198 |
Note 9 - Commitments and Cont_2
Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 06, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating Lease, Expense | $ 1 | $ 1.1 | $ 1.1 | |
Enma Sagastume v. Psychemedics Corporation [Member] | ||||
Litigation Settlement, Amount Awarded to Other Party | $ 1.2 | |||
Loss Contingency Accrual, Ending Balance | $ 1.2 |
Note 10 - Operating Leases (Det
Note 10 - Operating Leases (Details Textual) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating Lease, Weighted Average Discount Rate, Percent | 3.80% | ||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 3 years 2 months 12 days | ||
Operating Lease, Expense | $ 1 | $ 1.1 | $ 1.1 |
Note 10 - Operating Leases - Ma
Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
2023 | $ 1,134 | |
2024 | 1,061 | |
2025 | 553 | |
2026 | 460 | |
Total lease payments | 3,208 | |
Less: interest | (233) | |
Present value of lease liabilities | 2,975 | |
Current operating lease liabilities | 1,037 | $ 984 |
Long-term operating lease liabilities | 1,938 | $ 2,880 |
Total | $ 2,975 |
Note 11 - Debt and Other Fina_3
Note 11 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | 68 Months Ended | |||||
May 01, 2020 | Dec. 02, 2019 | Oct. 30, 2017 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 04, 2019 | |
Interest Expense, Total | $ 32 | $ 49 | $ 75 | ||||
Paycheck Protection Program CARES Act [Member] | |||||||
Proceeds from Issuance of Long-term Debt, Total | $ 2,100 | 0 | 0 | $ 2,181 | |||
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member] | |||||||
Interest Expense, Total | $ 16,000 | 32 | |||||
Debt Instrument, Term (Month) | 60 months | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 3.79% | ||||||
Proceeds from Issuance of Long-term Debt, Total | $ 12,200 | ||||||
Repayments of Long-term Debt, Total | 700 | $ 700 | |||||
Long-Term Debt, Total | $ 600 | ||||||
Long-Term Debt, Weighted Average Interest Rate, over Time | 3.70% | ||||||
Debt, Weighted Average Interest Rate | 3.80% | ||||||
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member] | |||||||
Debt Instrument, Basis Spread on Variable Rate | 1.75% |
Note 11 - Debt and Other Fina_4
Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Less current portion of long-term debt from equipment financing | $ (294) | $ (664) |
Long-term debt from equipment financing, net of current portion | 305 | $ 599 |
Equipment Loan Arrangement [Member] | ||
2023 | 294 | |
2024 | 305 | |
Long-term debt from equipment financing | 599 | |
Less current portion of long-term debt from equipment financing | (294) | |
Long-term debt from equipment financing, net of current portion | $ 305 |
Note 12 - Other Income (Expen_2
Note 12 - Other Income (Expense) (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Interest Expense, Total | $ 32 | $ 49 | $ 75 |
Interest Income, Other | $ 0 | $ 0 |
Note 13 - Business Segment Re_3
Note 13 - Business Segment Reporting (Details Textual) | 12 Months Ended |
Dec. 31, 2022 | |
Number of Operating Segments | 1 |
Note 13 - Business Segment Re_4
Note 13 - Business Segment Reporting - Revenue by Major Source (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues | $ 25,240 | $ 24,909 | $ 21,360 |
UNITED STATES | |||
Revenues | 24,509 | 23,584 | 19,486 |
Non-US [Member] | |||
Revenues | $ 731 | $ 1,325 | $ 1,874 |
Note 14 - Subsequent Event (Det
Note 14 - Subsequent Event (Details Textual) - $ / shares | 12 Months Ended | |||
Mar. 21, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Common Stock, Dividends, Per Share, Declared (in dollars per share) | $ 0.21 | $ 0.05 | $ 0.18 | |
Subsequent Event [Member] | ||||
Common Stock, Dividends, Per Share, Declared (in dollars per share) | $ 0.07 |